key: cord-0984759-dt67mw53
authors: Gargouri, Mohamed; Alzwi, Aboubaker; Abobaker, Anis
title: Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19
date: 2020-11-08
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.110380
sha: c804da24ce6c95b327ea9c001895972dbbf93e81
doc_id: 984759
cord_uid: dt67mw53

nan

general, viruses modify CDKs signalling pathway and regulate cell division cycle in a way that leads to enhancement of viral replication (1) . A recent evidence showed that the novel coronavirus (SARS-CoV-2) increases phosphorylation of CDK2 which affects its activities and subsequently leads to cell cycle arrest (2) . The same effect was observed with coronavirus infectious bronchitis virus and other RNA viruses (2) . Host Cell division cycle arrest provides supply of essential nucleotide and DNA repair and replication proteins which are essential for viral replication (2) . It has been noticed that CDKs are required for replication of DNA and RNA viruses (3) . Experiments showed that cyclin dependent kinase inhibitors (CDKIs) decrease replication of DNA There is limited evidence for the possible beneficial effect of CDKIs in management of COVID-19. It is argued that CGP-604747 drug, a CDKI, might have a role in management of lung injury induced by COVID-19 (7) . RNA sequencing of human lung tissues from two COVID-19 patients showed that CGP-604747 decreased expression of markers genes for lung injury (7) . Moreover, dinaciclib showed a strong antiviral activity against SARS-CoV-2 in two cell lines (2) . Although these findings are considered as promising results, the therapeutic effect of this drug class cannot be confirmed without randomised control trials (RCTs) to prove the efficacy of CDKIs. As CDKIs interfere with cell cycle regulation, there is a concern that this drug class might have a cytotoxic effect.

Low molecular weight CDKIs such as flavopiridol and roscovitine showed no toxicity in human clinical trials against cancer (3). However, CDK 4/6 inhibitors such as palbociclib, ribociclib and abemaciclib, had few significant adverse events during the management of breast cancer, which include neutropenia, prolongation of QTc interval and hepatotoxicity (8) . Therefore, RCTs are required to test the safety of using CDKIs to manage patients with COVID-19 on short-term basis.

In conclusion, CDKIs can be considered as a new treatment option in COVID-19 based on their proven experimental antiviral effect, broad spectrum antiviral activity, less risk of development of viral resistance and relative safety profile according to the results from cancer clinical trials. Therefore, a randomised clinical trial should be conducted in patients with COVID-19 to test the efficacy and safety of this drug class in management of this viral disease.

Gargouri, M: designed the main ideas of the study and revised the manuscript for important intellectual content Alzwi, A: revised the manuscript for important intellectual content Abobaker, A: drafted the initial manuscript

Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication

Potential Use of Pharmacological Cyclin-Dependent Kinase Inhibitors as Anti-HIV Therapeutics

Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral

Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. ASSAY and Drug Development Technologies

Prediction of repurposed drugs for treating lung injury in COVID-19

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitorbased treatment in breast cancer